TPST (Tempest Therapeutics) Scaled Net Operating Assets : 0.17 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Tempest Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Tempest Therapeutics's operating assets for the quarter that ended in Sep. 2024 was $11.72 Mil. Tempest Therapeutics's operating liabilities for the quarter that ended in Sep. 2024 was $4.64 Mil. Tempest Therapeutics's Total Assets for the quarter that ended in Jun. 2024 was $42.17 Mil. Therefore, Tempest Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.17.

Tempest Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for Tempest Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tempest Therapeutics Scaled Net Operating Assets Chart

Tempest Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

-3.73

0.12

0.18

Tempest Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Scaled Net Operating Assets	Get a 7-Day Free Trial													0.28	0.34	0.17	0.14	0.17

Competitive Comparison of Tempest Therapeutics's Scaled Net Operating Assets

For the Biotechnology subindustry, Tempest Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tempest Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Tempest Therapeutics's Scaled Net Operating Assets falls into.

Tempest Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Tempest Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(12.373	-	4.174)	/	46.089
=	0.18

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	51.603	-	39.23
=	12.373

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	24.835	-	15.424	-	5.237
=	4.174

Tempest Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Sep. 2024 )
=	(Operating Assets (Q: Sep. 2024 )	-	Operating Liabilities (Q: Sep. 2024 ))	/	Total Assets (Q: Jun. 2024 )
=	(11.72	-	4.641)	/	42.169
=	0.17

where

	Operating Assets		(Q: Sep. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	33.836	-	22.116
=	11.72

	Operating Liabilities		(Q: Sep. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	22.379	-	8.406	-	9.332
=	4.641

Tempest Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Tempest Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Tempest Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tempest Therapeutics Inc (NAS:TPST) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

3OS:Germany

Address

2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005

Website

https://www.tempesttx.com

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Executives

Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Stephen R Brady	director, officer: Chief Executive Officer	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Samuel Whiting	officer: Chief Medical Officer	C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Justin Trojanowski	officer: Corporate Controller	C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Nicholas Maestas	officer: VP of Strategy and Finance	7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 20005
Versant Ventures Vi Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Iv, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Thomas Woiwode	director, 10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Thomas W. Dubensky	director, officer: President	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710